2. Search Result
Search Result
Results for "

MDR1-MDCK

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156207
    C2 Adamantanyl globotriaosylceramide (d18:1/2:0)

    AdaGb3; Adamantyl Gb3; C2 Adamantanyl Ceramide Trihexoside (d18:1/2:0)

    		 P-glycoprotein Cancer
    C2 Adamantanyl globotriaosylceramide (d18:1/2:0) (AdaGb3), a water-soluble globotriaosylceramide analog, is a bioactive sphingolipid. C2 Adamantanyl globotriaosylceramide (d18:1/2:0) reverses MDR1-MDCK cell drug resistance. C2 Adamantanyl globotriaosylceramide (d18:1/2:0) has high affinity for verotoxin (VT) [1] .
    C2 Adamantanyl globotriaosylceramide (d18:1/2:0)
  • HY-161879
    WEE1-IN-9

    		Wee1 Cancer
    WEE1-IN-9 (Compound 1) is a Wee1 inhibitor that can be used in cancer research [1].
    WEE1-IN-9
  • HY-153510
    PHD-1-IN-2

    		HIF/HIF Prolyl-Hydroxylase Neurological Disease Inflammation/Immunology
    PHD-1-IN-2 is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase domain 1 (PHD-1) with an IC50 of 0.07 μM. PHD-1-IN-2 acts as a substrate of MDR1 in MDR1-MDCK cell monolayer assays. PHD-1-IN-2 can be used in the research of ischemia, inflammatory responses and neurodegenerative diseases, such as inflammatory bowel disease and ischemia-reperfusion injury [1].
    PHD-1-IN-2
  • HY-11014
    NB-216

    		Beta-secretase Cathepsin Neurological Disease
    NB-216 is an orally active and brain-penetrant BACE-1 inhibitor (IC50 = 17 nM). NB-216 has a strong inhibitory effect on cathepsin D (IC50 = 1 nM) and cathepsin E (IC50 = 0.4 nM). NB-216 can be used for the study of Alzheimer's disease [1].
    NB-216
  • HY-153513
    PHD-1-IN-4

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    PHD-1-IN-4 is a brain-penetrant PHD-1 inhibitor with an IC50 of 0.074 μM [1].
    PHD-1-IN-4
  • HY-153512
    PHD-1-IN-3

    		HIF/HIF Prolyl-Hydroxylase Others
    PHD-1-IN-3 is an orally active PHD-1 inhibitor with an IC50 of 0.09 μM. PHD-1-IN-3 acts via monodentate binding interaction with active site Fe 2+ ion [1].
    PHD-1-IN-3
  • HY-181543
    CVN14

    		CD38 Neurological Disease
    CVN14 is a potent, selective and brain-penetrant CD38 inhibitor with human IC50 19 nM, mouse IC50 2.4 nM. CVN14 binds uncompetitively to form a complex with CD38 and ADPR, and inhibits CD38 enzymatic activity. CVN14 can be used for the research of neurodegenerative diseases [1].
    CVN14
  • HY-183149
    BPN-37440

    		Prostaglandin Receptor Interleukin Related COX Neurological Disease
    BPN-37440 is a blood-brain barrier-permeable, selective, and orally active EP2 receptor inhibitor with an IC50 of 53-60 nM. BPN-37440 inhibits the expression of inflammatory mediators IL-1β and COX-2, with an IC50 of 21 nM for IL-1β and 42 nM for COX-2. BPN-37440 reduces microgliosis in key brain regions of mice with pilocarpine (HY-B0726A)-induced status epilepticus and reverses their working memory and recognition memory deficits. BPN-37440 can be used for research on status epilepticus [1].
    BPN-37440
  • HY-183557
    O-GlcNAcase-IN-6

    		OGA Neurological Disease
    O-GlcNAcase-IN-6 is an orally active, blood-brain barrier-permeable O-GlcNAcase (OGA) inhibitor with an IC50 of 5.4 nM. O-GlcNAcase-IN-6 inhibits OGA activity, thereby increasing the level of O-GlcNAc glycosylation in brain tissues. O-GlcNAcase-IN-6 can be used for the research of Alzheimer's disease [1].
    O-GlcNAcase-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: